STOCK TITAN

Adma Biologics Inc - ADMA STOCK NEWS

Welcome to our dedicated news page for Adma Biologics (Ticker: ADMA), a resource for investors and traders seeking the latest updates and insights on Adma Biologics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adma Biologics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adma Biologics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.19%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.18%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.48%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.67%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.77%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
Adma Biologics Inc

Nasdaq:ADMA

ADMA Rankings

ADMA Stock Data

1.37B
223.72M
2.63%
77.45%
3.2%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Ramsey

About ADMA

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.